Downregulation of p53 at therapeutic lithium concentrations in cultured neurons exposed to glutamate suggests that treating HD transcriptional dysregulation by p53 upregulation may be inviable for lithium, however replication across HD models is needed. This evidence concerns the gene TP53 and Huntington disease.